Phase 4 N=4,262 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.
Prospective · Single-blind · Clinical
Primary: All-cause Hospitalisations — 637; 633 Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Auto-antibodies Prevalence and CD1 Role in Gaucher Disease
Gaucher Disease
Primary: Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity <15% in Blood Leucocytes Completed When Necsssary by GB1…
Phase 3 N=872 Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
HIV · HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 — 93.1; 92.8 percentage of participants — p=0.78
Phase 3 N=412 Lurasidone Low-Dose - High-Dose Study Study
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 for Lurasidone 20 mg and 80-160 mg Versus Placebo. — -17.6; -24.9; -14.5 units…
Phase 3 N=349 Does Endometrial Injury Improve Intrauterine Insemination Outcome?
Infertility
Primary: Chemical Pregnancy Rate — 40; 19 participants
Phase 4 N=92 Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease
Hyperbilirubinemia · Erythroblastosis, Fetal
Primary: Need of Exchange Transfusion — 6; 7 participants — p=0.765
Phase 3 N=872 Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
HIV · HIV Infections
Primary: Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48 — 91.6; 88.5 percentage of participants — p=0.13
N/A N=3,215 A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)
Dyslipidemia · Hypercholesterolemia
Primary: Rate of Cardiovascular (CV) Events — 7.91; 10.79; 12.77; 13.4 Events per 1000 patient-years
Phase 4 N=174 Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept
Psoriasis
Primary: Time-Normalized Area Under Curve (AUC) of Physician Global Assessment (PGA) of Psoriasis Score at Week 52 — 1.64; 1.33 Units on a scale
Phase 2 N=77 Parent-Based Treatment for Pediatric Overweight
Overweight · Obesity
Primary: BMI Z Score — 2.3; 2.4 Z-score
Phase 2 N=171 Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 — 88.4; 89.7 percentage of participants — p=0.58
Phase 1 N=16 A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
HIV Infections
Primary: Area Under the Plasma Concentration-Time Curve From Time of Administration to 12 Hours After Dosing (AUC 0-12h) of Saquinavir (SQV) and Ritonavir (RTV) — 28518; 24332…
Phase 3 N=1,684 The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
Coronary Artery Disease
Primary: Percentage of Participants With Target Lesion Failure (TLF) at 12 Months — 6.4; 6.4 percentage of participants
Phase 2 N=83 Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848
Allergic Rhinitis
Primary: Mean of Reflective (10 Min) Total Nasal Symptom Score (TNSS) — 4.52; 4.97; 4.69 Scores on a scale
N/A N=26 Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change in the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) at Post-treatment and 3-month Follow-up. — 25.31; 20.75; 12.10; 14.38 units on a…